The stock of Rallybio Corp (RLYB) has gone down by -12.63% for the week, with a -11.77% drop in the past month and a -18.19% drop in the past quarter. The volatility ratio for the week is 8.71%, and the volatility levels for the past 30 days are 8.11% for RLYB. The simple moving average for the past 20 days is -19.42% for RLYB’s stock, with a -36.12% simple moving average for the past 200 days.
Is It Worth Investing in Rallybio Corp (NASDAQ: RLYB) Right Now?
Moreover, the 36-month beta value for RLYB is -1.51. Analysts have varying opinions on the stock, with 3 analysts rating it as a “buy,” 2 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for RLYB is 20.18M and currently, short sellers hold a 1.67% of that float. On December 26, 2024, RLYB’s average trading volume was 82.98K shares.
RLYB) stock’s latest price update
Rallybio Corp (NASDAQ: RLYB) has experienced a decline in its stock price by -5.95 compared to its previous closing price of 0.91. However, the company has seen a fall of -12.63% in its stock price over the last five trading days. businesswire.com reported 2024-12-10 that NEW HAVEN, Conn.–(BUSINESS WIRE)–Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today announced the presentation of two posters highlighting promising preclinical data for pipeline candidates RLYB212 and RLYB332 at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition, taking place December 7–10, 2024 in San Diego, California. “With our.
Analysts’ Opinion of RLYB
Jefferies, on the other hand, stated in their research note that they expect to see RLYB reach a price target of $1.50, previously predicting the price at $7. The rating they have provided for RLYB stocks is “Hold” according to the report published on February 07th, 2024.
H.C. Wainwright gave a rating of “Buy” to RLYB, setting the target price at $18 in the report published on April 17th of the previous year.
RLYB Trading at -18.02% from the 50-Day Moving Average
After a stumble in the market that brought RLYB to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -75.23% of loss for the given period.
Volatility was left at 8.11%, however, over the last 30 days, the volatility rate increased by 8.71%, as shares sank -18.37% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -20.64% lower at present.
During the last 5 trading sessions, RLYB fell by -16.79%, which changed the moving average for the period of 200-days by -53.42% in comparison to the 20-day moving average, which settled at $1.0615. In addition, Rallybio Corp saw -62.35% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for RLYB
Current profitability levels for the company are sitting at:
- -84.75 for the present operating margin
- 0.87 for the gross margin
The net margin for Rallybio Corp stands at -81.08. The total capital return value is set at -0.99. Equity return is now at value -68.90, with -63.12 for asset returns.
Currently, EBITDA for the company is -72.37 million with net debt to EBITDA at 0.36. When we switch over and look at the enterprise to sales, we see a ratio of 12.67. The liquidity ratio also appears to be rather interesting for investors as it stands at 9.55.
Conclusion
To wrap up, the performance of Rallybio Corp (RLYB) has been bad in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
